Celgene Corporation (CELG): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Celgene Corporation (CELG) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole was unchanged today. By the end of trading, Celgene Corporation fell 89 cents (-1.1%) to $81.19 on average volume. Throughout the day, 3.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.6 million shares. The stock ranged in price between $81.15-$82 after having opened the day at $81.89 as compared to the previous trading day's close of $82.08. Other companies within the Health Care sector that declined today were: Acura Pharmaceuticals (ACUR), down 15.2%, USMD Holdings (USMD), down 12.7%, IsoRay (ISR), down 11.5%, and MEI Pharma (MEIP), down 10.2%.

• EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $34.05 billion and is part of the drugs industry. The company has a P/E ratio of 22.4, above the S&P 500 P/E ratio of 17.7. Shares are up 19.1% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

• You can view the full Celgene Ratings Report.

On the positive front, YM Biosciences (YMI), up 76.7%, Idera Pharmaceuticals (IDRA), up 35.3%, AspenBio Pharma (APPY), up 30.1%, and ARCA biopharma (ABIO), up 24.3%, were all gainers within the health care sector with Illumina (ILMN) being today's featured health care sector leader.

• Use our health care section to find sector-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

• Find other investment ideas from our top rated ETFs lists.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.

For more information on Celgene Corporation click any of the following:

• Celgene Corporation Stock Price

• Celgene Corporation Analyst Ratings

• Celgene Corporation Key Stats & Profile

• Celgene Corporation Earnings

• Celgene Corporation Ratio Comparison

• Celgene Corporation Growth Rates

• Celgene Corporation Balance Sheet

• Celgene Corporation Cash Flow

• Celgene Corporation Income Statement